Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML

Cook, Jacqueline A; Lott, Loren; Perry, Jenna; Eckel, Ashley M; Xu, Dongbin; Hudson, Chad A; Wells, Denise A; Loken, Michael R; Menssen, Andrew J

doi:10.1182/blood.2024024264

Molecular measurable residual disease (MRD) can persist in core binding factor acute myeloid leukemia (AML) in otherwise disease-free patients. Utilizing cell sorting followed by fluorescent in situ hybridization, we show that detection is due to mast cells.

This content is only available as a PDF.

2024

You do not currently have access to this content.

Sign in via your Institution

Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML

Article PDF first page preview

24-Hour Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML

Article PDF first page preview

This feature is available to Subscribers Only

My Account

My Account

24-Hour Access

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only